公开(公告)号：US20220033407A1

公开(公告)日：2022-02-03

申请号：US17414672

申请日：2019-12-13

Applicant: NOVARTIS AG

Inventor： Mihai D. Azimioara ,  Bei Chen ,  Robert Epple ,  Declan Hardy ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Fabio Meier ,  Truc Ngoc Nguyen ,  Barun Okram ,  Sejal Patel ,  Rodrigo Rodriguez ,  Duncan Shaw ,  Yiping Shen ,  Baogen WU

IPC: C07D487/10 ,  C07D401/04 ,  C07D213/74 ,  C07D413/04 ,  C07D491/107 ,  A61K45/06

Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US20230365571A1

公开(公告)日：2023-11-16

申请号：US18044455

申请日：2021-09-15

Applicant: Novartis AG

Inventor： Trixi Brandl ,  Claus Ehrhardt ,  Robert Epple ,  Christian Markert ,  Pascal Rigollier ,  Juraj Velcicky

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.

公开(公告)号：US20200002281A1

公开(公告)日：2020-01-02

申请号：US16566083

申请日：2019-09-10

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  Truc Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US10450273B2

公开(公告)日：2019-10-22

申请号：US15688089

申请日：2017-08-28

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  Truc Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  C07D401/12 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US11066369B2

公开(公告)日：2021-07-20

申请号：US16566083

申请日：2019-09-10

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  True Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D401/02 ,  C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  C07D401/12 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.